Lysophosphatidic acid reduces the organ injury caused by endotoxemia-A role for G-protein-coupled receptors and peroxisome proliferator-activated receptor-γ

Shock

Volumn 27, Issue 1, 2007, Pages 48-54

  Murch, Oliver ^a   Collin, Marika ^a   Thiemermann, Christoph ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

GW9662; Ki16425; LPS; Peroxisome proliferator activated receptor ; Sepsis

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1BETA; KI 16425; LIPOPOLYSACCHARIDE; LYSOPHOSPHATIDIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENDOTOXEMIA; MALE; NONHUMAN; ORGAN INJURY; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTOXEMIA; LIVER; LYSOPHOSPHOLIPIDS; MALE; NEUROMUSCULAR DISEASES; PPAR GAMMA; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 33845710345     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000235086.63723.7e     Document Type: Article

References (32)

1. Graler MH, Goetzl EJ: Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta 1582:168-174, 2002.
2. Gueguen G, Gaige B, Grevy JM, Rogalle P, Bellan J, Wilson M, Klaebe A, Pont F, Simon MF, Chap H: Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation. Biochemistry 38:8440-8450, 1999.
3. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G: Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol 280:R466-R472, 2001.
4. Moolenaar WH, van Meeteren LA, Giepmans BN: The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870-881, 2004.
5. Noguchi K, Ishii S, Shimizu T: Identification of P2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the edg family. J Biol Chem 278:25600-25606, 2003.
6. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, et al.: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 100:131-136, 2003.
7. Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, Marathe GK, McIntyre TM, Xu Y, Prestwich GD, et al.: Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med 199:763-774, 2004.
8. Jiang C, Ting AT, Seed B: PPAR-Gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998.
9. Asada K, Sasaki S, Suda T, Chida K, Nakamura H: Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 169:195-200, 2004.
10. Collin M, Patel NS, Dugo L, Thiemermann C: Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med 32:826-831, 2004.
11. Kaplan JM, Cook JA, Hake PW, O'Connor M, Burroughs TJ, Zingarelli B: 15-Deoxy-Delta(12,14)-Prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 24:59-65, 2005.
12. Dugo L, Collin M, Cuzzocrea S, Thiemermann C: 15d-Prostaglandin J2 reduces multiple organ failure caused by wall-fragment of gram-positive and gram-negative bacteria. Eur J Pharmacol 498:295-301, 2004.
13. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, Cook JA: Peroxisome proliferator activator receptor-gamma ligands, 15-Deoxy-Delta (12, 14)-Prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171:6827-6837, 2003.
14. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Fulia F, Cuzzocrea E, et al.: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 32:457-466, 2004.
15. Abdelrahman M, Collin M, Thiemermann C: The peroxisome proliferator-activated receptor-gamma ligand 15-deoxydelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock 22:555-561, 2004.
16. Zingarelli B, Cook JA: Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23:393-399, 2005.
17. de Vries B, Matthijsen RA, van Bijnen AA, Wolfs TG, Buurman WA: Lysophosphatidic acid prevents renal ischemia-reperfusion injury by inhibition of apoptosis and complement activation. Am J Pathol 163:47-56, 2003.
18. Demoyer JS, Skalak TC, Durieux ME: Lysophosphatidic acid enhances healing of acute cutaneous wounds in the mouse. Wound Repair Regen 8:530-537, 2000.
19. Sturm A, Zeeh J, Sudermann T, Rath H, Gerken G, Dignass AU: Lisofylline and lysophospholipids ameliorate experimental colitis in rats. Digestion 66:23-29, 2002.
20. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C: Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 23:267-276, 2003.
21. Millar CG, Thiemermann C: Carboxy-PTIO, a scavenger of nitric oxide, selectively inhibits the increase in medullary perfusion and improves renal function in endotoxemia. Shock 18:64-68, 2002.
22. Hewett JA, Jean PA, Kunkel SL, Roth RA: Relationship between tumor necrosis factor-alpha and neutrophils in endotoxin-induced liver injury. Am J Physiol 265:G1011-G1015, 1993.
23. Ruetten H, Southan GJ, Abate A, Thiemermann C: Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 118:261-270, 1996.
24. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al.: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650, 2002.
25. Dugo L, Abdelrahman M, Murch O, Mazzon E, Cuzzocrea S, Thiemermann C: Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 25:485-491, 2006.
26. Collin M, Anuar FB, Murch O, Bhatia M, Moore PK, Thiemermann C: Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br J Pharmacol 146:498-505, 2005.
27. Wray GM, Millar CG, Hinds CJ, Thiemermann C: Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. Shock 9:329-335, 1998.
28. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, Louhelainen M, Foster SJ, Yaqoob MM, Thiemermann C: GSK-3beta Inhibitors Attenuate the Organ Injury/Dysfunction Caused by Endotoxemia in the Rat. Crit Care Med 33:1903-1912, 2005.
29. LeDoux D, Astiz ME, Carpati CM, Rackow EC: Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 28:2729-2732, 2000.
30. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, et al.: Ki16425, a Subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64:994-1005, 2003.
31. Huang MC, Graeler M, Shankar G, Spencer J, Goetzl EJ: Lysophospholipid mediators of immunity and neoplasia. Biochim Biophys Acta 1582:161-167, 2002.
32. Gobeil F Jr, Bernier SG, Vazquez-Tello A, Brault S, Beauchamp MH, Quiniou C, Marrache AM, Checchin D, Sennlaub F, Hou X, Nader M, Bkaily G, Ribeiro-da-Silva A, Goetzl EJ, Chemtob S: Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J Biol Chem 278:38875-38883, 2003.